Deal Spotlight
Sep 20, 2026September 20, 2026
Exciva raises EUR51M in Series B with EQT Life Sciences and GIMV
EUR51M
round size
seed
stage
The Series B round closed on September 15, 2026, with participation from EQT Life Sciences and GIMV. To date, the company has raised EUR118.2M across four funding rounds.
Exciva develops innovative therapeutic solutions for neurological diseases, focusing on epilepsy and other neurological disorders. The company is based in Germany and operates in Healthcare & Life Sciences at the seed stage. It was founded by Mark Altmeyer.
Brouky tracks 192 Healthcare & Life Sciences deals in Germany over the past twelve months, with a median investment amount of EUR10M.
Related insights
- Deal SpotlightMoffett AI raises EUR130M in Series C+ backed by Biqiu Capital and others
- Deal SpotlightYazen Health raises EUR50M Series B backed by Evli Growth Partners and Helsana
- Deal SpotlightAerium raises EUR2.3M Seed with Gutter Capital participating
- Deal SpotlightPhoton Bridge raises EUR10M Series A backed by 360 Capital and Amadeus Capital Partners
Explore the full dataset
Brouky tracks 37,000+ investors and 122,000+ investments across 134,000+ startups. Search by country, stage, and sector.